Intrahepatic, Perihilar and Distal Cholangiocarcinoma: Management and Outcomes

Abstract

Introduction & Aims Cholangiocarcinomas are a heterogeneous group of tumors that can be classified into three clinically distinct types of cancers, intrahepatic, perihilar and distal cholangiocarcinoma. The inconsistent use of nomenclature for these cancers has obscured a true knowledge of the epidemiology, natural history and response to therapy of these cancers. Our aims were to define demographic characteristics, management and outcomes of these three distinct cancer types. Materials and Methods A retrospectivestudy of patients enrolled in an institutional cancer registry from 1992 to 2010. Median survival was compared between different treatment modalities over three time periods for the three types of cholangiocarcinoma at different stages of the disease using Kaplan Meyer analysis. Results 242 patients were identified. All cases were reviewed and classified into intrahepatic (90 patients), distal (48 patients) or perihilar (104 patients) cholangiocarcinomas These cancers differed in median age of onset, gender distribution, median survival and stage. 13.8% of patients presented with stage I, 5.8% with stage II, 9.6% with stage III, 28% with stage IV, with 41.8% having unknown stage. The overall median survival was 15.8 months, and was 23, 25, 14, and 4.5 months for stages I, II, III, and IV respectively. Surgery improved survival in both early and advanced stages. Multimodality therapies further improved outcomes, particularly for perihilar cholangiocarcinoma. Conclusion Perihilar, distal and intrahepatic cholangiocarcinoma vary in their presentation, natural history and therapeutic approach to management. A consistently applied classification is essential for meaningful interpretation of studies of these cancers.

Near‐infrared photoimmunotherapy (NIR‐PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes

“…Cholangiocarcinoma (CCA) is relatively rare and accounts for about 3% of all gastrointestinal cancers in the United States and 5% in Japan. The overall 5‐y survival rate of CCA is 20%‐30% with a poor prognosis secondary to only to pancreatic cancer 1,2 . The reason for this low survival rate is the limited CCA treatment methods available.…”

Serum mucin 3A as a potential biomarker for extrahepatic cholangiocarcinoma

“…[ 5 ] Therefore, more than 2/3 of EHCC patients with definitive diagnoses are in late stage and have missed the opportunity for radical surgery. [ 6 ] The survival time of patients with unresectable EHCC was usually only 6-9 months. [ 2 ]…”

The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective

“…Indeed, the interaction of cancer cells and the host microenvironment plays a critical role in strengthening the metastatic proficiency. Thus, a better understanding of the oncological drivers of these tumors, including their interaction with the microenvironment, is of utmost importance [15, 16]. In this review, we will focus on the role of these tumor-associated cells in the tumorigenesis and progression of GI cancers, as well as on their role in treatment resistance and potential targeted therapeutic approaches.…”